The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1356
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
The full article is available to subscribers Subscriber Login   

The FDA has approved ceftaroline fosamil (Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), and for treatment of community-acquired bacterial pneumonia in adults. It is the first beta-lactam antibiotic approved for treatment of MRSA.

MECHANISM OF ACTION — Like other beta-lactams, ceftaroline binds to penicillin-binding proteins (PBPs), inhibiting cell wall synthesis. Unlike other currently available beta-lactams, it has a high affinity in vitro for PBP2a, a unique PBP encoded by the mecA gene in MRSA.1

STANDARD TREATMENT2Skin and Skin-Structure InfectionUncomplicated skin and skinstructure ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Article code: 1356a
 Electronic, downloadable article - $25